2 news items
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
LRMR
20 May 24
in the 50 mg cohort achieved frataxin levels in skin cells over 33% of the average level observed in healthy volunteers at Day 14, and 3 patients
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
LRMR
9 May 24
% of the average level observed in healthy volunteers, with 3 patients achieving levels greater than 50% of the average healthy volunteer level
- Prev
- 1
- Next